Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation

Journal of Translational Medicine

David T Harris¹  John Pierce²  Angela Muise¹  Michael Badowski¹  Mahmood S Choudhery¹ 

[1] Department of Immunobiology, College of Medicine, The University of Arizona, PO Box 245221, 85724, Tucson, AZ, USA;Aesthetic Surgery of Tucson, Tucson, AZ, USA

关键词: In vitro differentiation potential;    Growth kinetics;    Regenerative potential;    Donor age;    Mesenchymal stem cells;    Adipose tissue;   

Others  :  822238
DOI  :  10.1186/1479-5876-12-8

 received in 2013-09-23, accepted in 2013-12-03,  发布年份 2014

【 摘 要 】

Background

Human adipose tissue is an ideal autologous source of mesenchymal stem cells (MSCs) for various regenerative medicine and tissue engineering strategies. Aged patients are one of the primary target populations for many promising applications. It has long been known that advanced age is negatively correlated with an organism’s reparative and regenerative potential, but little and conflicting information is available about the effects of age on the quality of human adipose tissue derived MSCs (hAT-MSCs).

Methods

To study the influence of age, the expansion and in vitro differentiation potential of hAT-MSCs from young (<30 years), adult (35-50 years) and aged (>60 years) individuals were investigated. MSCs were characterized for expression of the genes p16^INK4a and p21 along with measurements of population doublings (PD), superoxide dismutase (SOD) activity, cellular senescence and differentiation potential.

Results

Aged MSCs displayed senescent features when compared with cells isolated from young donors, concomitant with reduced viability and proliferation. These features were also associated with significantly reduced differentiation potential in aged MSCs compared to young MSCs.

Conclusions

In conclusion, advancing age negatively impacts stem cell function and such age related alterations may be detrimental for successful stem cell therapies.

【 授权许可】

   
2014 Choudhery et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Pérez-Simon JA, López-Villar O, Andreu EJ, Rifón J, Muntion S, Campelo MD, Sánchez-Guijo FM, Martinez C, Valcarcel D, Cañizo CD: Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 2011, 96(7):1072-1076.
• [2]Choudhery MS, Khan M, Mahmood R, Mohsin S, Akhtar S, Ali F, Khan SN, Riazuddin S: Mesenchymal stem cells conditioned with glucose depletion augments their ability to repair -infarcted myocardium. J Cell Mol Med 2012, 16(10):2518-2529.
• [3]Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
• [4]Lee CC, Ye F, Tarantal AF: Comparison of growth and differentiation of fetal and adult rhesus monkey mesenchymal stem cells. Stem Cells Dev 2006, 15(2):209-220.
• [5]Choudhery MS, Badowski M, Muise A, Harris DT: Comparison of human adipose and cord tissue derived mesenchymal stem cells. Cytotherapy 2013, 15(3):330-343.
• [6]Ryan JM, Barry F, Murphy JM, Mahon BP: Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007, 149(2):353-363.
• [7]Abumaree M, Al Jumah M, Pace RA, Kalionis B: Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev 2012, 8(2):375-392.
• [8]Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baumgartner WW, Martin BJ, Heldman AW, Hare JM: Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 2005, 102(32):11474-11479.
• [9]Xin H, Li Y, Shen LH, Liu X, Wang X, Zhang J, Pourabdollah-Nejad DS, Zhang C, Zhang L, Jiang H, Zhang ZG, Chopp M: Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse. PLoS One 2010, 5(2):e9027.
• [10]Taylor SE, Smith RK, Clegg PD: Mesenchymal stem cell therapy in equine musculoskeletal disease: scientific fact or clinical fiction? Equine Vet J 2007, 39(2):172-180.
• [11]Kretlow JD, Jin YQ, Liu W, Zhang WJ, Hong TH, Zhou G, Baggett LS, Mikos AG, Cao Y: Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol 2008, 9:60. BioMed Central Full Text
• [12]Choudhery MS, Khan M, Mahmood R, Mehmood A, Khan SN, Riazuddin S: Bone marrow derived mesenchymal stem cells from aged mice have reduced wound healing, angiogenesis, proliferation and anti-apoptosis capabilities. Cell Biol Int 2012, 36(8):747-753.
• [13]Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13(12):4279-4295.
• [14]Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH: Multi-lineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001, 7(2):211-228.
• [15]Zhu M, Kohan E, Bradley J, Hedrick M, Benhaim P, Zuk P: The effect of age on osteogenic, adipogenic and proliferative potential of female adipose-derived stem cells. J Tissue Eng Regen Med 2009, 3(4):290-301.
• [16]Giovannini S, Diaz-Romero J, Aigner T, Heini P, Mainil-Varlet P, Nesic D: Micromass co-culture of human articular chondrocytes and human bone marrow mesenchymal stem cells to investigate stable neocartilage tissue formation in vitro. Eur Cell Mater 2010, 20:245-259.
• [17]Kim WK, Jung H, Kim DH, Kim EY, Chung JW, Cho YS, Park SG, Park BC, Ko Y, Bae KH, Lee SC: Regulation of adipogenic differentiation by LAR tyrosine phosphatase in human mesenchymal stem cells and 3T3-L1 preadipoctes. J Cell Sci 2009, 122(pt 22):4160-4167.
• [18]Nalesso G, Sherwood J, Bertrand J, Pap T, Ramachandran M, De Bari C, Pitzalis C, Dell’accio F: WNT-3A modulates articular chondrocyte phenotype by activating both canonical and noncanonical pathways. J Cell Biol 2011, 193(3):551-564.
• [19]Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells: the international society for cellular therapy position statement. Cytotherapy 2006, 8(4):315-317.
• [20]Alt EU, Senst C, Murthy SN, Slakey DP, Dupin CL, Chaffin AE, Kadowitz PJ, Izadpanah R: Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res 2012, 8(2):215-225.
• [21]Capparelli C, Chiavarina B, Whitaker-Menezes D, Pestell TG, Pestell RG, Hulit J, Andò S, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP: CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 2012, 11(19):3599-3610.
• [22]Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995, 92(20):9363-9367.
• [23]Menicanin D, Bartold PM, Zannettino AC, Gronthos S: Genomic profiling of mesenchymal stem cells. Stem Cell Rev Rep 2009, 5(1):36-50.
• [24]Stolzing A, Jones E, McGonagle D, Scutt A: Age-related changes in human bone marrow derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008, 129(3):163-173.
• [25]Jurgens WJ, Oedayrajsingh-Varma MJ, Helder MN, Zandiehdoulabi B, Schouten TE, Kuik DJ, Ritt MJ, Van Milligen FJ: Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies. Cell Tissue Res 2008, 332(3):415-426.
• [26]Gonzalez R, Griparic L, Vargas V, Burgee K, Santacruz P, Anderson R, Schiewe M, Silva F, Patel A: A putative mesenchymal stem cells population isolated from adult human testes. Biochem Biophys Res Commun 2009, 385(4):570-575.
• [27]Erickson GR, Gimble JM, Franklin DM, Rice HE, Awad H, Guilak F: Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivo. Biochem Biophys Res Commun 2002, 290(2):763-769.
• [28]Jang S, Cho HH, Cho YB, Park JS, Jeong HS: Functional neural differentiation of human adipose tissue-derived stem cells using bFGF and forskolin. BMC Cell Biol 2010, 11:25. BioMed Central Full Text
• [29]Dimmeler S, Leri A: Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008, 102(11):1319-1330.
• [30]Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A: Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2003, 42(12):2073-2080.
• [31]Tokalov SV, Grüner S, Schindler S, Wolf G, Baumann M, Abolmaali N: Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats. Stem Cells Dev 2003, 16(3):439-446.
• [32]Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ: Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 1999, 107(2):275-281.
• [33]Robinson JA, Harris SA, Riggs BL, Spelsberg TC: Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology 1997, 138(7):2919-2917.
• [34]Ankrom MA, Patterson JA, d’Avis PY, Vetter UK, Blackman MR, Sponseller PD, Tayback M, Robey PG, Shapiro JR, Fedarko NS: Age-related changes in human oestrogen receptor α function and levels in steoblasts. Biochem J 1998, 333(Pt 3):787-794.
• [35]Shi YY, Nacamuli RP, Salim A, Longaker MT: The osteogenic potential of adipose-derived mesenchymal cells is maintained with aging. Plast Reconstr Surg 2005, 116(6):1686-1696.
• [36]Khan WS, Adesida AB, Tew SR, Andrew JG, Hardingham TE: The epitope characterisation and the osteogenic differentiation potential of human fat pad-derived stem cells is maintained with ageing in later life. Injury 2009, 40(2):150-157.
• [37]Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F: Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 2002, 46(3):704-713.